All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
51st Annual Meeting of the EBMT congress coverage
Bookmark this article
Stay up to date with the latest developments in multiple myeloma with our live social media coverage from the 51st Annual Meeting of the EBMT, March 30 – April 2, 2025, Florence, Italy.
CONGRESS | #EBMT25 | PRESENTATION
— Multiple Myeloma Hub (@MM_Hub) April 3, 2025
Maria Victoria Mateos MRD as a surrogate marker for outcomes in #myeloma, highlighting that recognition of MRD as a regulatory endpoint represents a milestone in myeloma care and will facilite data driven, patient-centered precision medicine.… pic.twitter.com/XuturukRLC
CONGRESS | #EBMT25 | POSTER
— Multiple Myeloma Hub (@MM_Hub) April 3, 2025
Martin Vogel shares findings from post hoc analyses describing cilta-cel efficacy by response to bridging therapy in patients who received cilta-cel as study treatment in the phase III CARTITUDE-4 trial (N = 176).
Greater response to bridging therapy… pic.twitter.com/NfdP3IFSDi
CONGRESS | #EBMT25 | PRESENTATION@MirghSumeet, @ACTREC_TMC, shares findings from a 15-year retrospective institutional study comparing melphalan >140-200 mg/m2 (Mel-200; n = 134) and ≤140 mg/m2 (Mel-140; n = 42) conditioning in patients with #MultipleMyeloma. At a median… pic.twitter.com/5K5nKAMLSY
— Multiple Myeloma Hub (@MM_Hub) April 2, 2025
CONGRESS | #EBMT25 | PRESENTATION
— Multiple Myeloma Hub (@MM_Hub) April 2, 2025
Kiavasch Mohammad Nejad Farid, Heidelberg University Hospital, Germany, discusses compassionate use of BCMA-directed MDC-CAR-BCMA001 in extremely difficult-to-treat patients with #MultipleMyeloma (n = 3) and AL amyloidosis (n = 3). ORR was… pic.twitter.com/nJAU70PiAc
CONGRESS | #EBMT25 @TheEBMT| PRESENTATION
— Multiple Myeloma Hub (@MM_Hub) April 2, 2025
María-Victoria Mateos, @usal, discusses long term findings from the phase III CARTITUDE-4 study of cilta-cel vs SoC in patients with lenalidomide-refractory #MultipleMyeloma. At a median follow-up of 34 months, cilta-cel significantly… pic.twitter.com/6XTidvXXze
CONGRESS | #EBMT25 | PRESENTATION
— Multiple Myeloma Hub (@MM_Hub) April 2, 2025
Thierry Facon @ThierryFacon @univ_lille discussed the place of auto- and allo-HSCT in patients with ND multiple #myeloma, covering:
▪️Quadruplet regimens followed by ASCT as SoC in patients aged < 70 years with ND MM.
▪️Transplant as a piece of a… pic.twitter.com/T1gTjIReuA
CONGRESS | #EBMT25 @TheEBMT | PRESENTATION
— Multiple Myeloma Hub (@MM_Hub) April 2, 2025
Mario Boccadoro, @unito, presents results from an expanded analysis of the phase III PERSEUS trial (NCT03710603) showing that daratumumab plus bortezumab, lenalidomide, and dexamethasone (D-VRd) induction/consolidation followed by… pic.twitter.com/YuTFYJi7Fc
CONGRESS | #EBMT25 | PRESENTATION
— Multiple Myeloma Hub (@MM_Hub) April 1, 2025
Marcelo Pasquini @mpasca @MedicalCollege discusses CAR T-cell therapies for patients with multiple myeloma in the real-world setting.
They highlight results from real-world studies, and discuss potential challenges and future directions.@TheEBMT… pic.twitter.com/R0l5o47OF2
CONGRESS | #EBMT25 | PRESENTATION
— Multiple Myeloma Hub (@MM_Hub) April 1, 2025
Mohamad Mohty @Mohty_EBMT @Sorbonne_Univ_ discusses CAR T-cell therapies in patients with multiple myeloma.
They discuss future directions, including to use of CAR T-cells in earlier lines of therapy and novel constructs, manufacturing processes,… pic.twitter.com/B7AO1gXO7w
CONGRESS | #EBMT25 | PRESENTATION
— Multiple Myeloma Hub (@MM_Hub) April 1, 2025
Francesca Gay @unito provides an overview of new therapies for patients with RRMM.
They discuss results from several key clinical trials and highlight the need for novel agents for later lines of therapy.@TheEBMT #mmsm #myeloma #MedicalCongress pic.twitter.com/BLjQx3pLaC
CONGRESS | #EBMT25 @TheEBMT | PRESENTATION@MinnemaMonique discusses the sequencing of bispecific antibodies and CAR-T cell therapy in #MultipleMyeloma, suggesting the need to space treatments as long as possible, particularly when transitioning from a BsAb to other BsAb or a… pic.twitter.com/acPg4FDdoP
— Multiple Myeloma Hub (@MM_Hub) April 1, 2025
Your opinion matters
0 votes - 27 days left ...
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox